A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.
about
Safety and efficacy of azacitidine in myelodysplastic syndromesMyelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and managementSome aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversyMDS prognostic scoring systems – past, present, and futureRefractory anemia with ring sideroblasts and RARS with thrombocytosisManagement of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data.Treatment options for myelodysplastic syndromes.Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome.Myelodysplastic syndromes: Contemporary review and how we treat.Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantationHematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care.Demethylating Agents in the Treatment of CancerPrognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO studyHematopoietic stem cell transplantation for MDS.Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndromeAllogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control studyCurrent therapy of myelodysplastic syndromesShould elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrThere's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysisValue of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: BloodMyelodysplastic syndromes: diagnosis, prognosis, and treatment.Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantationAlemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.Role and timing of hematopoietic cell transplantation for myelodysplastic syndrome.Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.Hypomethylating agents and other novel strategies in myelodysplastic syndromes.The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions?Evidence-based mini-review: Should patients over the age of 60 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia?Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.
P2860
Q24596561-0FFB0C88-A747-4EA2-A21B-7713149A878CQ26796240-65C25C09-E517-4F81-AF14-E557320A9B69Q27010653-2E3C3642-EAB7-4959-AEEF-85DC59F2EE1AQ28082460-174B03D8-3D12-4E58-86BC-ED035041FEFBQ28083238-166EF853-9C7E-44AE-9E48-615545BA98FBQ30235355-C1B0A719-2286-4207-8BEA-368AE7D71EC4Q30252975-841A74A1-E3BA-49AC-AD0C-BDE2623548F8Q30353404-325E5B8F-ABB2-4B87-88CE-AC74C1C3518EQ30675919-28E383A7-4730-4D1B-9A90-44A74D1947ECQ33364350-55A9FB06-BA34-480C-AA42-1934DF4192D2Q33379562-FF8D5423-DA9D-4000-B34C-22089A86A14BQ33393647-2E7F46A9-F429-4113-A004-1EFD7C33445CQ33395648-C4C39EF4-896B-476D-BCC8-44D8DEEEF43EQ33429195-570AF966-F52D-4AC1-8592-F7E603ADFE61Q33615619-9854CD15-3EFE-4D1C-8658-4F06749C2765Q33652781-A3F42441-EA90-4B95-B101-AAD465476FDBQ33678040-E5B42015-B81D-4142-B3FD-8C75EA09D2E0Q33707461-3181F0CA-EDDC-4150-92F8-B1E81B28A5F2Q33767314-54638E1F-48CB-4421-B2B1-206C050E5556Q33856597-6D2E808A-2276-4079-97A8-360D51265C1DQ33856972-AC8247B9-28FA-4F8A-A02B-9B507F1C3F75Q34013796-D7A94DC5-0B56-47CD-8901-213D56ED463BQ34013826-20C43E11-B67D-45E8-B080-4E8A4E738CEDQ34044024-77374E29-FCD4-48FF-8B01-F496FE189427Q34049017-2459E593-04C5-4110-AFFE-A93A578E0A32Q34099792-4E0EA7E8-789B-40D9-855A-0D593CACF8A8Q34166581-0858BE7D-16E7-49B5-A69C-6FD54851F79EQ34187884-367E200E-8369-4674-9C59-2AADAA944D50Q34217884-6A565022-326B-49B8-9BCF-678838B1B357Q34389508-FCDD52DA-9640-4D1E-8A1A-27C671CD03DEQ34396189-7F96E840-939A-40AF-8089-03CB71172AA9Q34488656-58167EE4-A1DE-41CC-9937-FA71F3C079CEQ34549306-B9D011BE-7666-4A73-BEFF-E68AE041DBB5Q34612644-6EE3E1BB-C47E-407F-AABA-C6D2B74B2ADCQ34667051-ACA50D72-7474-41B9-A1C5-465939B010B9Q34714792-E3328BFD-15D6-4B55-B14E-D6566179D643Q35202588-24C0DC9F-9975-4D96-B341-051FE64E73C0Q35265820-8B548ED3-BBC2-4B8E-9E52-5C2F16658BC0Q35317371-C0071533-62A7-4373-ABF2-4D3EFE8FFBCEQ35634902-59EBCEFE-05A6-470B-9DAB-228AF613B058
P2860
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A decision analysis of allogen ...... ociated with improved outcome.
@ast
A decision analysis of allogen ...... ociated with improved outcome.
@en
A decision analysis of allogen ...... ociated with improved outcome.
@nl
type
label
A decision analysis of allogen ...... ociated with improved outcome.
@ast
A decision analysis of allogen ...... ociated with improved outcome.
@en
A decision analysis of allogen ...... ociated with improved outcome.
@nl
prefLabel
A decision analysis of allogen ...... ociated with improved outcome.
@ast
A decision analysis of allogen ...... ociated with improved outcome.
@en
A decision analysis of allogen ...... ociated with improved outcome.
@nl
P2093
P50
P1433
P1476
A decision analysis of allogen ...... ociated with improved outcome.
@en
P2093
Armand Keating
Brian J Bolwell
Claudio Anasetti
Corey S Cutler
Daniel J Weisdorf
Gustavo A Milone
J Douglas Rizzo
Jane L Liesveld
John P Klein
Joseph H Antin
P304
P356
10.1182/BLOOD-2004-01-0338
P407
P577
2004-03-23T00:00:00Z